61
Daniel P Becker, Daniel L Flynn, Alan E Moormann, Roger Nosal, Clara I Villamil: Imidazopyridines as serotonergic 5-HT.sub.3 antagonists. G D Searle & Co, Cynthia S Kovacevic, Roger A Williams, July 18, 1995: US05434161 (24 worldwide citation)

The imidazopyridines compounds of the present invention are serotonergic 5-HT.sub.3 antagonists. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT.sub.3 receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses ...


62
David Alker, Peter E Cross: Piperidine and pyrrolidine derivatives. Pfizer, Peter C Richardson, Paul H Ginsburg, Garth Butterfield, September 6, 1994: US05344835 (24 worldwide citation)

According to the invention there is provided a compound of formula (I): R.sup.1 --O(CH.sub.2).sub.m A(CH.sub.2).sub.n XR or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a group of formula (a or b) where Z is --(CH.sub.2).sub.2-, --CH.dbd.CH--, --CH.sub.2 --S-- or --CH.sub.2 --O--; ...


63
Robert G Pendleton: .alpha..sub.2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility. William H Nicholson, Michael C Sudol, June 16, 1987: US04673680 (24 worldwide citation)

Selective .alpha..sub.2 -adrenergic receptor antagonists are effective in modifying gastrointestinal motility in a manner useful in the treatment of colonic spasm, irritable bowel syndrome and constipation.


64
Peter E Cross, Alexander R MacKenzie: Pyrrolidine derivatives. Pfizer, Peter C Richardson, Paul H Ginsburg, Seymour G Bekelnitzky, August 3, 1993: US05233053 (24 worldwide citation)

Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altere ...


65
Mitsuaki Ohta, Takeshi Suzuki, Jun ya Ohmori, Keiji Miyata, Isao Yanagisawa: Method of treatment of intestinal diseases. Yamanouchi Pharmaceutical, Burgess Ryan and Wayne, August 20, 1996: US05547961 (24 worldwide citation)

A method is provided for the treatment of hypersensitive intestinal diseases (irritable bowel syndrome) comprising the administration of a tetrahydroimidazopyridine derivative of the formula: ##STR1## wherein either one of X and Y is nitrogen and the other one is a radical represented by the formula ...


66
Geoffrey Gymer, Kiyoshi Kawamura, Sachiko Mihara, Mikio Morita, Alan Stobie, Chikara Uchida, Seiji Nukui: Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators. Pfizer, Gregg C Benson, Frank W Forman, December 27, 2005: US06979690 (23 worldwide citation)

This invention provides compounds of the formula (I) and (II): or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R2 and R3 are independently hydrogen or C1-6 alkyl; R4 and R5 are independently hydrogen or C1-6 alkyl; ...


67
Alverdy John C: Modulation of microbial pathogen-host cell interactions. The University Of Chicago, Alverdy John C, MERKEL William K, December 14, 2006: WO/2006/132963 (23 worldwide citation)

The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound ...


68
Barry D Quart, David P Rosenbaum: Method for treatment of constipation-predominant irritable bowel syndrome. Napo Pharmaceuaticals, McCarter & English, Jonathan M Sparks, Marcie B Clarke, November 29, 2011: US08067041 (22 worldwide citation)

The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant ...


69
Florence Rochat, Olivier Ballevre, Alfred Jann: Method of treating irritable bowel syndrome. Nestec, Bell Boyd & Lloyd, November 28, 2006: US07141554 (22 worldwide citation)

A nutritional composition is disclosed which comprises synergistic functional carbohydrates for preventing or treating infection by pathogenic bacteria and/or promoting gut flora balance and health. The carbohydrates have a synergistic activity on promoting bifidobacteria in the intestine. Also disc ...


70
Jaswant S Gidda, John M Schaus: Isoxazole derivatives for the treatment of irritable bowel syndrome. Eli Lilly and Company, Douglas J Taylor, July 18, 1995: US05434174 (22 worldwide citation)

Methods of treating Irritable Bowel Syndrome (IBS) using a series of isoxazole derivatives that have both 5-HT1A agonist and M1 muscarinic activities, and formulations adapted for the treatment of IBS comprising those derivatives.